drugset / Trial / NCT00433667

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

NCT00433667

Phase 3 Completed 563 enrolled SK Life Science, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.

Timeline

Start
2006-11
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 200 mg Oral
Subject Carisbamate Small molecule 400 mg Oral